Related Experiment Video

Updated: Aug 7, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K

Novel Migraine Treatments: A Review

Naveen George, Stewart J Tepper

    Journal of Oral & Facial Pain and Headache
    |March 14, 2023
    PubMed

    More Related Videos

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders05:49

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

    Published on: November 1, 2024

    866
    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache05:40

    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

    Published on: July 29, 2021

    8.1K

    Related Concept Videos

    Antidepressant Drugs: MAOIs and Other Agents01:23

    Antidepressant Drugs: MAOIs and Other Agents

    Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
    289
    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
    223
    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

    5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
    279
    Open Angle Glaucoma: Treatment01:27

    Open Angle Glaucoma: Treatment

    In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
    Drugs such as carbonic anhydrase inhibitors, α2- and...
    511
    Management of Insomnia01:19

    Management of Insomnia

    The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
    294
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
    1.7K